+44 20 3868 9735
UC-II® is a unique joint health ingredient derived from chicken sternum. In a previous study, UC-II® improved knee extension range of motion and extend exercise time before the onset of knee pain in healthy participants. The current exploratory post hoc analyses sought to assess items from the Knee Injury and Osteoarthritis Outcome Score (KOOS) in healthy participants aged ≥ 50 years who previously participated in a randomized controlled trial. All participants reported knee pain following a standardized stepmill test and were randomized to receive placebo or 40 mg UC-II® supplementation containing ≥ 3% (≥ 1.2 mg) undenatured type II collagen for 120 days. For the current post hoc analyses, 17 participants (UC-II® =9, placebo=8) met the acceptance criteria (age ≥ 50 years). Analysis was carried out for the KOOS survey results with modified Intent-To-Treat Analysis (mITT). P-values ≤ 0.05 were considered statistically significant. After 120 days of supplementation, participants in the UC-II® supplementation group exhibited statistically significant improvements versus the placebo in select KOOS items including reduced pain during going up or down stairs, decreased discomfort in climbing ascending stairs or bending to floor to pick an object, or squatting during physical activity (p<0.05). UC-II® supplementation has the potential to improve knee joint function, mobility, flexibility, free movements and performance of daily activities in healthy participants ≥ 50 years old with exercise-induced knee pain.
Published Date: 2021-12-28; Received Date: 2021-12-07